Certa Therapeutics awarded $25m funding with support from MRCF and Uniseed
Melbourne, Australia, 04 June 2018: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce A$25m in funding has been received. Certa Therapeutics, led by CEO and founder Professor Darren Kelly has been awarded A$22 million by the Biomedical Translation Fund (BTF), […]
Australian Financial Review – Biomedical Translation Fund helps keep kidney disease pharma in Australia
The $500 million Biomedical Translation Fund has made its biggest investment yet, tipping $22 million into Certa Therapeutics to enable the Melbourne-based start-up to carry out clinical trials of potential lifesaving kidney disease treatments in Australia. Certa, based at founder Darren Kelly’s University of Melbourne laboratories, aims to advance the use of DNA testing to […]